A systematic literature review of clinical trials and therapeutic applications of ibogaine
- PMID: 35012793
- DOI: 10.1016/j.jsat.2021.108717
A systematic literature review of clinical trials and therapeutic applications of ibogaine
Abstract
Background: Iboga and its primary alkaloids, ibogaine and noribogaine, have been of interest to researchers and practitioners, mainly due to their putative efficacy in treating substance use disorders (SUDs). For many SUDs, still no effective pharmacotherapies exist. Distinct psychoactive and somatic effects of the iboga alkaloids set them apart from classic hallucinogens like LSD, mescaline, and psilocybin.
Aims: The study team performed this systematic review focusing on clinical data and therapeutic interventions involving ibogaine and noribogaine.
Methods: The team conducted a search for all publications up to December 7, 2020, using PubMed and Embase following PRISMA guidelines.
Results: In total, we identified 743 records. In this review, we consider 24 studies, which included 705 individuals receiving ibogaine or noribogaine. This review includes two randomized, double-blind, controlled clinical trials, one double-blind controlled clinical trial, 17 open-label studies or case series (including observational or retrospective studies), three case reports, and one retrospective survey. The published data suggest that ibogaine is an effective therapeutic intervention within the context of SUDs, reducing withdrawal symptoms and craving. Data also point toward a beneficial impact on depressive and trauma-related psychological symptoms. However, studies have reported severe medical complications and deaths, which seem to be associated with neuro- and cardiotoxic effects of ibogaine. Two of these fatalities were described in the 24 studies included in this review.
Conclusion: Treatment of SUDs and persisting comorbidities requires innovative treatment approaches. Rapid-onset therapies such as the application of ibogaine may offer novel treatment opportunities for specific individuals. Rigorous study designs within medical settings are necessary to warrant safe application, monitoring, and, possibly, medical intervention.
Keywords: Cocaine; Hallucinogen; Opioid; Psychedelic; Substance use disorder; Treatment.
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Ibogaine/Noribogaine in the Treatment of Substance Use Disorders: A Systematic Review of the Current Literature.Curr Neuropharmacol. 2023;21(11):2178-2194. doi: 10.2174/1570159X21666221017085612. Curr Neuropharmacol. 2023. PMID: 36263479 Free PMC article.
-
IUPHAR - invited review - Ibogaine - A legacy within the current renaissance of psychedelic therapy.Pharmacol Res. 2023 Apr;190:106620. doi: 10.1016/j.phrs.2022.106620. Epub 2023 Mar 11. Pharmacol Res. 2023. PMID: 36907284 Review.
-
Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: A mechanistic overview.J Psychopharmacol. 2023 Dec;37(12):1190-1200. doi: 10.1177/02698811231200882. Epub 2023 Nov 8. J Psychopharmacol. 2023. PMID: 37937505 Review.
-
Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine.J Psychoactive Drugs. 2018 Jul-Aug;50(3):256-265. doi: 10.1080/02791072.2018.1447175. Epub 2018 Apr 2. J Psychoactive Drugs. 2018. PMID: 29608409
-
Psychedelic Therapy: A Primer for Primary Care Clinicians-Ibogaine.Am J Ther. 2024 Mar-Apr 01;31(2):e133-e140. doi: 10.1097/MJT.0000000000001723. Am J Ther. 2024. PMID: 38518270
Cited by
-
The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients.J Psychopharmacol. 2024 May;38(5):481-488. doi: 10.1177/02698811241237873. Epub 2024 Mar 22. J Psychopharmacol. 2024. PMID: 38519421 Free PMC article.
-
Evolution and diversification of carboxylesterase-like [4+2] cyclases in aspidosperma and iboga alkaloid biosynthesis.Proc Natl Acad Sci U S A. 2024 Feb 13;121(7):e2318586121. doi: 10.1073/pnas.2318586121. Epub 2024 Feb 6. Proc Natl Acad Sci U S A. 2024. PMID: 38319969 Free PMC article.
-
The Nonclassic Psychedelic Ibogaine Disrupts Cognitive Maps.Biol Psychiatry Glob Open Sci. 2023 Aug 5;4(1):275-283. doi: 10.1016/j.bpsgos.2023.07.008. eCollection 2024 Jan. Biol Psychiatry Glob Open Sci. 2023. PMID: 38298796 Free PMC article.
-
5-HT2A Receptor Knockout Mice Show Sex-Dependent Differences following Acute Noribogaine Administration.Int J Mol Sci. 2024 Jan 5;25(2):687. doi: 10.3390/ijms25020687. Int J Mol Sci. 2024. PMID: 38255760 Free PMC article.
-
Key Characteristics and Development of Psychoceuticals: A Review.Int J Mol Sci. 2022 Dec 12;23(24):15777. doi: 10.3390/ijms232415777. Int J Mol Sci. 2022. PMID: 36555419 Free PMC article. Review.